Intrahepatic Cholangiocarcinoma Clinical Trials 2023

Intrahepatic Cholangiocarcinoma Clinical Trials 2023

Intrahepatic Cholangiocarcinoma research studies recruiting patients in 2023 need your help. Receive premium care & cutting edge treatments by enrolling in intrahepatic cholangiocarcinoma clinical trials today.

Intrahepatic Cholangiocarcinoma Clinical Trials

Here are the 6 most popular medical studies for intrahepatic cholangiocarcinoma

Popular filter options for intrahepatic cholangiocarcinoma trials

Bile Duct Cancer Clinical Trials

View 60 Bile Duct Cancer medical studies.

EBD Cancer Clinical Trials

View 58 EBD Cancer medical studies.

FGFR2 Positive Clinical Trials

View 9 FGFR2 positive medical studies.

IDH Positive Clinical Trials

View 6 IDH positive medical studies.

Phase 3 Intrahepatic Cholangiocarcinoma Clinical Trials

View 98 phase 3 intrahepatic cholangiocarcinoma medical studies.

Intrahepatic Cholangiocarcinoma Clinical Trials With No Placebo

View 98 intrahepatic cholangiocarcinoma medical studies that do not have a placebo group.

View More Intrahepatic Cholangiocarcinoma Trials

See another 70 medical studies focused on intrahepatic cholangiocarcinoma.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to intrahepatic cholangiocarcinoma

What are the top hospitals conducting intrahepatic cholangiocarcinoma research?

Intrahepatic cholangiocarcinoma, a rare and aggressive form of liver cancer, has spurred renowned hospitals across the United States to conduct groundbreaking clinical trials in search of effective treatments. Memorial Sloan Kettering Cancer Center in New york leads the charge with 13 active trials dedicated to this condition and a cumulative total of 25 trials since their first recorded exploration in 2000. Meanwhile, Massachusetts General Hospital in Boston follows closely behind with nine ongoing intrahepatic cholangiocarcinoma trials and an impressive history of 19 previous studies dating back to their inaugural trial in 2006.

The University of Texas MD Anderson Cancer Center, located in Houston, is also playing a significant role by conducting eight active clinical trials for intrahepatic cholangiocarcinoma. Their commitment to research began more recently with their first recorded trial occurring just seven years ago in 2014. Additionally, another institution within the MD Anderson network joins the fight against this challenging disease as they too have conducted eight active clinical tests alongside fifteen past investigations since initiating their pioneering study on intrahepatic cholangiocarcinoma starting from 2011.

Lastly but not leastly; yet another branch from M D Anderson Cancer Center based out at Houston has made its own mark by actively spearheading six current explorations while carrying out sixteen former efforts after taking initiative commencing only around decade ago,in year2014to broaden horizons for such patients battling against Intraheptic Chlangocarcoma

These esteemed hospitals are at the forefront of cutting-edge research into finding better treatment options for those affected by intrahepatic cholangiocarcinoma. With each new trial and every breakthrough discovery, we move one step closer towards improving outcomes and offering hope to individuals facing this formidable disease.

Which are the best cities for intrahepatic cholangiocarcinoma clinical trials?

When it comes to clinical trials for intrahepatic cholangiocarcinoma, several cities in the United States are leading the way. Houston, Texas stands out with 37 active trials, investigating treatments like NGM831 and RLY-4008. New york City and Boston tie at 32 active trials each, exploring options such as gavo-cel and Cobimetinib respectively. Los Angeles, California follows closely behind with 26 ongoing studies focused on Nivolumab and pembrolizumab among others. While Anchorage, Alaska also has 26 active trials underway examining treatments like Arm B (pevonedistat, paclitaxel, carboplatin) and Cisplatin. These cities offer individuals diagnosed with intrahepatic cholangiocarcinoma access to cutting-edge clinical research that may lead to better treatment outcomes and improved quality of life.

Which are the top treatments for intrahepatic cholangiocarcinoma being explored in clinical trials?

Clinical trials are exploring various treatments to combat intrahepatic cholangiocarcinoma, a challenging form of cancer. Among the leading contenders are gemcitabine, having 5 active and 51 all-time trials since its introduction in 2002; durvalumab with 2 ongoing and a total of 16 clinical trials for this specific type of cancer since it first appeared in 2016; tivozanib, a newcomer with two current studies and two overall trials dedicated to intrahepatic cholangiocarcinoma starting from its listing in 2021; and olaparib, also involved in two active trials out of five cumulative investigations focused on this disease since being listed as a potential treatment option in 2019. These advancements offer hope for patients battling intrahepatic cholangiocarcinoma.

What are the most recent clinical trials for intrahepatic cholangiocarcinoma?

Exciting advancements are underway in the field of intrahepatic cholangiocarcinoma, with recent clinical trials offering promising prospects for patients. One notable trial is evaluating the efficacy of Tinengotinib 8 mg QD as a potential treatment option in Phase 3. Additionally, Phase 2 trials are exploring various approaches such as Arm A and Gemcitabine + Cisplatin + Durvalumab + Yttrium-90 Selective Internal Radiation Therapy to address this challenging cancer type. These studies aim to uncover new strategies and therapeutic combinations that may significantly improve outcomes for individuals battling intrahepatic cholangiocarcinoma.

What intrahepatic cholangiocarcinoma clinical trials were recently completed?

Several clinical trials exploring innovative treatments for intrahepatic cholangiocarcinoma have recently concluded, signifying important progress in the field. In August 2020, Celldex Therapeutics completed a trial investigating CDX-527's potential as a targeted therapy. Similarly, the National Cancer Institute wrapped up their study on MVT-5873 in November 2019. Mayo Clinic also contributed to this research by completing a trial on Trifluridine and Tipiracil Hydrochloride in October 2019. These advancements underscore the commitment of researchers to finding new approaches to combatting intrahepatic cholangiocarcinoma and bring hope to patients facing this challenging disease.